Stocks Health care JANX
NASDAQ · Health careJanux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. brought in $23.3M of revenue over the twelve months to September 30, 2026, up 132.9% from a year earlier. It posted a net loss of $99.8M. In fiscal 2025 capital spending exceeded operating cash flow by $83.3M. At September 30, 2026 it held $41.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Janux Therapeutics, Inc.
- Net worth
- Janux Therapeutics, Inc. has a market value (market cap) of $780.1M at the latest share price, and shareholders' equity of $911.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $10M (-5.6% year on year), with a net loss of $113.6M. Over the 12 months to September 30, 2026: revenue $23.3M, net loss $99.8M.
- Cash flow
- In fiscal 2025 operations used $82.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Janux Therapeutics, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Janux Therapeutics, Inc. does
Janux Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker JANX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $10M | -$113.6M | -$1.83 | -$83.3M |
| 2024 | $10.6M | -$69M | -$1.28 | -$44.2M |
| 2023 | $8.1M | -$58.3M | -$1.32 | -$52.4M |
| 2022 | $8.6M | -$63.1M | -$1.52 | -$49.4M |
| 2021 | $3.6M | -$32.7M | -$1.39 | -$18.5M |
| 2021 | $0 | -$6.8M | -$7.41 | -$4.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where JANX ranks in Health care
Latest SEC filings
What Janux Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 7.1% to $9.3M versus the same quarter last year; diluted EPS -$0.34 versus -$0.39.
- November 5, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue was $10.3M; diluted EPS -$0.35 versus -$0.55.
- August 6, 2026
- July 28, 2026Passive stake changed SCHEDULE 13G/A
- June 23, 2026Other event 8-K
- June 12, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Janux Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 31, 2026 | Campbell David AlanPresident and CEO, Director | Gave as a gift | 123,840 | - |
| July 8, 2026 | Campbell David AlanPresident and CEO, Director | Exercised options | 7,000 | $29.5K |
| June 11, 2026 | Dobmeier EricDirector | Received as pay | 5,500 | - |
| June 11, 2026 | Ra Capital Management, L.P.Director, 10% owner | Received as payindirect | 5,500 | - |
| June 11, 2026 | Capps Vickie LDirector | Received as pay | 5,500 | - |
| June 11, 2026 | Barrett Ronald WDirector | Received as pay | 5,500 | - |
| June 11, 2026 | Kung WinstonDirector | Received as pay | 5,500 | - |
| June 11, 2026 | Hernday NatashaDirector | Received as pay | 5,500 | - |
Who owns JANX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Jay Lichter, Ph.D. (Lichter)13D, may seek influence with 12 related filers | 21.2% | November 16, 2023 |
| RA Capital Management, L.P.13D, may seek influence with 3 related filers | 19.9% | March 10, 2025 |
| W. Lawrence Hawkins13G, passive with 4 related filers | 5.3% | February 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 198 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| RA Capital Management, L.P. | 11,189,693 | 0 |
| BlackRock, Inc. | 6,134,667 | +701,434 |
| Prosight Management, LP | 3,804,481 | +254,481 |
| State Street Corp | 3,004,899 | +540,882 |
| Fmr LLC | 2,412,825 | -122,899 |
| Federated Hermes, Inc. | 2,352,927 | +2,298,727 |
| Point72 Asset Management, L.P. | 1,993,837 | +837,697 |
| Vanguard Capital Management LLC | 1,857,351 | +45,986 |
| TCG Crossover Management, LLC | 1,789,617 | 0 |
| Alyeska Investment Group, L.P. | 1,647,140 | +46,051 |
| Nantahala Capital Management, LLC | 1,619,828 | +809,914 |
| Wellington Management Group Llp | 1,507,360 | -90,290 |
| Vanguard Portfolio Management LLC | 1,330,710 | +40,454 |
| Two Sigma Investments, LP | 1,207,250 | +1,091,151 |
| Geode Capital Management, LLC | 1,204,150 | +57,426 |
| Citadel Advisors LLC | 1,200,737 | +848,560 |
| Algert Global LLC | 1,110,889 | +667,492 |
| D. E. Shaw & Co., Inc. | 1,096,509 | +998,114 |
| Goldman Sachs Group Inc | 952,675 | +350,662 |
| Bank of America Corp | 910,460 | +108,814 |
Insiders
15 insiders reported holding 972,040 shares in total, about $12.4M at the last price.
| Holder | Shares |
|---|---|
| Campbell David AlanPresident and CEO, Director | 264,742 |
| DiRaimondo ThomasChief Scientific Officer | 155,825 |
| Winter Charles M.Chief Technical Officer | 106,321 |
| Meyer Andrew HollmanChief Business Officer | 83,095 |
| Capps Vickie LDirector | 79,598 |
| Doyle Janeen NoelChief Corp. & Bus. Dev. Ofcr | 75,941 |
| McIver ZachariahChief Medical Officer | 52,286 |
| Go WilliamChief Medical Officer | 44,000 |
| Dobek MariaVice President, Accounting | 32,270 |
| Hernday NatashaDirector | 15,481 |
Questions about JANX
What does Janux Therapeutics, Inc. do?
Janux Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as JANX. Its shares trade on NASDAQ under the ticker JANX.
What is Janux Therapeutics, Inc.'s net worth?
Janux Therapeutics, Inc. has a market value (market cap) of $780.1M at the latest share price, and shareholders' equity of $911.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Janux Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $99.8M on revenue of $23.3M.
How much revenue does Janux Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 Janux Therapeutics, Inc. reported revenue of $23.3M. That is 132.9% more than a year earlier.
When did Janux Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Janux Therapeutics, Inc.'s next earnings report?
Janux Therapeutics, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare JANX with
Follow JANX
Get an email when Janux Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Janux Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.